Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models

Transfusion

Volumn 41, Issue 11, 2001, Pages 1438-1444

  Shi, Patricia A ^a,b   Pomper, Gregory J ^a,b   Metzger, Mark E ^a,b   Donahue, Robert E ^a,b   Leitman, Susan F ^a,b   Dunbar, Cynthia E ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

ANIMAL CELL; ARTICLE; CELL POPULATION; COLONY FORMING UNIT; HEMATOPOIETIC CELL; MACACA; NONHUMAN; STEM CELL;

ANIMALS; CELL DIVISION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; MACACA MULATTA; MICE; MICE, INBRED C57BL; STEM CELL FACTOR; TIME FACTORS;

EID: 0035190152     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41111438.x     Document Type: Article

References (42)

1. Transplantation of bone marrow as compared with peripheral-blood stem cells from HLA-identical relatives in patients with hematologic cancers
2. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures
3. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow
4. Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants
5. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support
6. Allogeneic blood stem cell transplantation: Peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease
7. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients
8. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia
9. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies
10. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
11. Transplantation tolerance induced by "mega dose" CD34+ cell transplants
12. Total therapy with tandem transplants for newly diagnosed multiple myeloma
13. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy
14. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma
15. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial
16. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer
17. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - Results of a phase I/II trial
18. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients
19. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
20. Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay
21. In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells
22. Bone marrow collected 14 days after in vivo administration of granulocyte colony-stimulating factor and stem cell factor to mice has 10-fold more repopulating ability than untreated bone marrow
23. Gene transfer into hematopoietic progenitor cells of nonhuman primates
24. Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor
25. Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential
26. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine
27. Competitive repopulation: A new assay for long-term stem cell functional capacity
28. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation
29. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
30. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia
31. The effect of granulocyte colony-stimulating factor administration in healthy donors before bone marrow harvesting
32. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and function
33. Avoidance of stimulation improves engraftment of cultured and retrovirally transduced hematopoietic cells in primates
34. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor
35. Homing and engraftment potential of Sca-1(+)lin(-) cells fractionated on the basis of adhesion molecule expression and position in cell cycle
36. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery
37. Peripheral blood stem cell apheresis in normal donors: Feasibility and yield of second collections
38. Repeated peripheral stem cell mobilization in healthy donors: Time-dependent changes in mobilization efficiency
39. Successful PBSC mobilization with high-dose G-CSF for patients failing a first round of mobilization
40. Factors influencing G-CSF-mediated mobilization of hematopoietic progenitor cells during steady-state hematopoiesis in patients with malignant lymphoma and multiple myeloma
41. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields